A July 2023 report from GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA) examined the impact of the COVID pandemic on the uptake of adult vaccination around the world. The report estimated approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, compounding already low adoption rates pre-pandemic. Data also showed that investment in adult vaccines represent less than 2% of total pharmaceutical spending in all regions. The analysis provides new evidence on why changes are needed, given existing data that show adult vaccine-preventable diseases are a major cause of morbidity, mortality and healthcare cost.